

## Searches for User *djagoe* (Count = 15979)

Queries 15930 through 15979.

Find

S #	Updt	Database	Query	Time	Comment
<u>S15979</u>	<u>U</u>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	6645972.pn.	2006-03-18 16:18:17	
<u>S15978</u>	<u>U</u>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(imatinib mesylate or gleevac or glivec or STE 571 ) and (suberoylanilide or vorinostat or SAHA! )	2006-03-18 15:00:42	
<u>S15977</u>	<u>U</u>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	suberoylanilide or vorinostat or SAHA!	2006-03-18 15:00:27	
<u>S15976</u>	<u>U</u>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(Bcr\$1Abl tyrosine kinase inhibitor ) and (histone deacetylase inhibitor )	2006-03-18 14:59:30	
<u>S15975</u>	<u>U</u>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	histone deacetylase inhibitor	2006-03-18 14:59:19	
<u>S15974</u>	<u>U</u>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	Bcr\$1Abl tyrosine kinase inhibitor	2006-03-18 14:58:43	
<u>S15973</u>	<u>U</u>	PGPB,USPT	Bcr\$1Abl tyrosine kinase inhibitor	2006-03-18 14:58:30	
<u>S15972</u>	<u>U</u>	PGPB,USPT	(20030166557 and saha! or suberoylanilide ) and (imatinib mesylate or gleevac or glivec or STE 571 )	2006-03-18 14:52:57	
<u>S15971</u>	<u>U</u>	PGPB,USPT	imatinib mesylate or gleevac or glivec or STE 571	2006-03-18 14:52:43	
<u>S15970</u>	<u>U</u>	PGPB,USPT	(20030166557 ) and (saha! or	2006-03-18	

Show Saved Searches

<u>S15969</u>	<u>U</u>	PGPB,USPT	suberoylanilide )	14:51:45
			(6645972.pn. ) and	2006-03-
			(histone deacetylase	18
			inhibitor )	14:43:51
<u>S15968</u>	<u>U</u>	PGPB,USPT	histone deacetylase	2006-03-
			inhibitor	18
				14:43:41
<u>S15967</u>	<u>U</u>	PGPB,USPT	(6645972.pn. ) and	2006-03-
			(saha! or	18
			suberoylanilide )	14:41:32
<u>S15966</u>	<u>U</u>	PGPB,USPT	saha! or suberoylanilide	2006-03-
				18
				14:41:01
<u>S15965</u>	<u>U</u>	PGPB,USPT	20030166557	2006-03-
				18
				14:18:29
<u>S15964</u>	<u>U</u>	PGPB,USPT	200300166557	2006-03-
				18
				14:18:22
<u>S15963</u>	<u>U</u>	PGPB,USPT	(Minna.in. ) and	2006-03-
			@pd=09042003	18
				14:17:59
<u>S15962</u>	<u>U</u>	PGPB,USPT	@pd=09042003	2006-03-
				18
				14:17:46
<u>S15961</u>	<u>U</u>	PGPB,USPT	Minna.in.	2006-03-
				18
				14:17:15
<u>S15960</u>	<u>U</u>	PGPB,USPT	2003/0166557	2006-03-
				18
				14:16:49
<u>S15959</u>	<u>U</u>	PGPB,USPT	6645972.pn.	2006-03-
				18
				14:16:28

Jagoe

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 220127-57-1 REGISTRY  
ED Entered STN: 03 Mar 1999  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CGP 57148B  
CN Gleevac  
CN Gleevec  
CN Glivec  
CN Imatinib mesilate  
CN **Imatinib mesylate**  
CN ~~STN 571~~

MF C29 H31 N7 O . C H4 O3 S

CI COM


SR CA

LC STN Files: ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, DDFU, DRUGU, EMBASE, HSDB\*, IMSPATENTS, IMSRESEARCH, MRCK\*, PATDPASPC, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



*Bcr-Abl TK inhib.*

*A61k 31/19  
514/575*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1195 REFERENCES IN FILE CA (1907 TO DATE)

15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1204 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Jagoe

=> s suberoylanilide hydromaxic acid

1 SUBEROYLANILIDE

0 HYDROMAXIC

7543010 ACID

L2 0 SUBEROYLANILIDE HYDROMAXIC ACID

(SUBEROYLANILIDE (W) HYDROMAXIC (W) ACID)

=> s suberoylanilide

L3 1 SUBEROYLANILIDE

=> d 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 149647-78-9 REGISTRY

ED Entered STN: 27 Aug 1993

CN Octanediamide, N-hydroxy-N'-phenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN SAHA

CN Suberoylanilide hydroxamic acid


CN Vorinostat

FS 3D CONCORD

MF C14 H20 N2 O3

SR CA

LC STN Files: AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CIN,  
IMSRESEARCH, IPA, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2,  
USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

218 REFERENCES IN FILE CA (1907 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

222 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Jagoe

L5 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1  
ACCESSION NUMBER: 2005:1313861 CAPLUS  
DOCUMENT NUMBER: 144:45450  
TITLE: Use of thioredoxin measurements for diagnostics and treatments  
INVENTOR(S): Marks, Paul A.; Ungerstedt, Johanna  
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA  
SOURCE: PCT Int. Appl., 81 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117930	A2	20051215	WO 2005-US19523	20050603
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-577089P P 20040604

IT 302-79-4, Retinoic acid 146426-40-6, Flavopiridol 154361-50-9, Capecitabine 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(co-treatment with; use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)

IT 55-21-0D, Benzamide, derivs. 60-01-5, Tributyrin 79-09-4, Propanoic acid, biological studies 89-73-6, Salicylohydroxamic acid 99-66-1, Valproic acid 103-82-2, Phenylacetic acid, biological studies 109-52-4, Pentanoic acid, biological studies 156-54-7, Sodium butyrate 503-74-2 541-35-5, Butyramide 563-83-7, Isobutyramide 1821-12-1, Benzenebutanoic acid 16336-88-2, 3-Bromopropionate 18992-11-5, Azelaic bishydroxamic acid 30240-06-3, MW2996 53342-16-8, Chlamydocin 58880-19-6, Trichostatin A 68676-88-0, Trichostatin C 83209-65-8, HC-toxin 112522-64-2, CI-994 128517-07-7, FR901228 133155-89-2, Trapoxin A 136268-96-7, MW2796 139508-73-9, Depudecin 149647-78-9, Suberoylanilide hydroxamic acid 149647-79-0 151720-43-3, Oxamflatin 174664-65-4, CBHA 174664-68-7 183506-66-3 191228-04-3, A-161906 209783-80-2, MS-27-275 209783-80-2D, MS-27-275, 3'-amino derivs. 258854-10-3, FR225497 287383-59-9, Scriptaid 382180-17-8, Pyroxamide 414864-00-9, PXD-101 442532-98-1, WF 27082 591207-53-3, LAQ 824 618056-29-4, CHAP

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)

Jagoe

L5 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2  
ACCESSION NUMBER: 2005:1004984 CAPLUS  
DOCUMENT NUMBER: 143:279368  
TITLE: Pharmacodynamic assays for measuring blood cell  
response to MS-275 and other histone deacetylase  
inhibitors using flow cytometry in leukemia therapy  
INVENTOR(S): Trepel, Jane; Chung, Eun Joo  
PATENT ASSIGNEE(S): The Government of the United States of America,  
Asrepresented by the Secretary of the Department of  
Health and Human Services, USA  
SOURCE: PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085864	A1	20050915	WO 2005-US6236	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-548794P P 20040227  
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT  
IT 60-01-5, Tributyrin 99-66-1, Valproic acid 103-82-2, Phenylacetic  
acid, biological studies 156-54-7, Sodium butyrate 1716-12-7, Sodium  
phenylbutyrate 16336-88-2, 3-Bromopropionate 58880-19-6, Trichostatin  
A 75747-14-7, 17-Allylaminogeldanamycin 112522-64-2, CI-994  
128517-07-7, Fk228 133155-89-2 149647-78-9, Suberoylanilide  
hydroxamic acid 151720-43-3, Oxamflatin 174664-65-4 209783-80-2,  
MS-275 220127-57-1, Imatinib mesylate 382180-17-8, Pyroxamide  
404951-53-7, NVP-LAQ824 414864-00-9, PXD101 618056-29-4, CHAP  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(pharmacodynamic assays for measuring blood cell response to MS-275 and  
other histone deacetylase inhibitors using flow cytometry in leukemia  
therapy)

L5 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
ACCESSION NUMBER: 2005:99470 CAPLUS  
DOCUMENT NUMBER: 142:197889  
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for  
treatment of raf, VEGFR, PDGFR, p38 and flt-3  
kinase-mediated diseases  
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm,  
Scott  
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA  
SOURCE: PCT Int. Appl., 68 pp.  
CODEN: PIXXD2



Jagoe

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005009961	A2	20050203	WO 2004-US23500	20040722
WO 2005009961	A3	20050331		
WO 2005009961	B1	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005038080	A1	20050217	US 2004-895985	20040722
PRIORITY APPLN. INFO.:			US 2003-489102P	P 20030723
			US 2004-540326P	P 20040202
IT	50-07-7, Mitomycin C	50-18-0, Cyclophosphamide	50-24-8, Prednisolone	
	50-44-2, 6-Mercaptopurine	50-76-0, Dactinomycin	50-91-9,	
	5-Fluorodeoxyuridine	51-21-8, 5-Fluorouracil	52-24-4, Thiotepa	
	53-03-2, Prednisone	53-19-0, Mitotane	55-98-1, Busulfan	56-53-1,
	Diethylstilbestrol	57-22-7, Vincristine	57-85-2, Testosterone	
	propionate	58-05-9, Leucovorin	58-96-8, Uridine	59-05-2,
	Methotrexate	71-58-9, Medroxyprogesterone acetate	76-43-7,	
	Fluoxymesterone	125-84-8, Aminogluthethimide	127-07-1, Hydroxyurea	
	134-46-3, 5-Fluorodeoxyuridine monophosphate	147-94-4, Cytarabine		
	148-82-3, Melphalan	154-42-7, Thioguanine	154-93-8, Carmustine	
	305-03-3, Chlorambucil	320-67-2, 5-Azacytidine	446-86-6, Azathioprine	
	595-33-5, Megestrol acetate	630-56-8, Hydroxyprogesterone caproate		
	645-05-6, Hexamethylmelamine	671-16-9, Procarbazine	865-21-4,	
	Vinblastine	3778-73-2, Ifosfamide	4291-63-8, Cladribine	4342-03-4,
	Dacarbazine	9015-68-3, Asparaginase	10540-29-1, Tamoxifen	
	11056-06-7, Bleomycin	13010-47-4, Lomustine	13311-84-7, Flutamide	
	13909-09-6, Semustine	15663-27-1, Cisplatin	18378-89-7, Plicamycin	
	18883-66-4, Streptozocin	19767-45-4, Mesna	20830-81-3, Daunorubicin	
	23214-92-8, Doxorubicin	25316-40-9, Adriamycin	29767-20-2, Teniposide	
	33069-62-4, Paclitaxel	33419-42-0, Etoposide	41575-94-4, Carboplatin	
	51321-79-0	53643-48-4, Vindesine	53910-25-1, Pentostatin	56420-45-2,
	Epirubicin	58957-92-9, Idarubicin	61825-94-3, Oxaliplatin	
	65271-80-9, Mitoxantrone	71486-22-1, Vinorelbine	75607-67-9,	
	Fludarabine phosphate	84449-90-1	85622-93-1, Temozolomide	
	95058-81-4, 2',2'-Difluorodeoxycytidine	114977-28-5, Docetaxel		
	123948-87-8, Topotecan	128517-07-7, FR-901228	149647-78-9,	
	Suberoylanilide hydroxamic acid	154361-50-9, Capecitabine	179324-69-7,	
	Bortezomib	180288-69-1, Trastuzumab	183319-69-9, OSI-774	
	184475-35-2, ZD-1839	205923-56-4, Cetuximab	208921-02-2, Tositumomab	
	209783-80-2, MS-275	212141-54-3, PTK 787	216974-75-3, Bevacizumab	
	220127-57-1, STI-571	257933-82-7, EKB-569	288383-20-0, AZD	
	2171	289499-45-2, CI-1033	380610-27-5, Pertuzumab	387867-13-2,
	MLN-518	437755-78-7, GW 2016	443913-73-3, ZD-6474	557795-19-4, SU
	11248	591207-53-3, LAQ 824	777080-36-1, AG 13736	804551-71-1, CHIR
	258			

Jagoe

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph  
urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated  
diseases)

L5 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2005:1355554 CAPLUS

DOCUMENT NUMBER: 144:81158

TITLE: Use of thioredoxin measurements for diagnostics and  
treatments

INVENTOR(S): Marks, Paul A.; Ungerstedt, Johanna

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S.  
Ser. No. 369,094.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2005288227	A1	20051229	US 2005-144301	20050603
US 2003235588	A1	20031225	US 2003-369094	20030214
US 2006009526	A1	20060112	US 2005-223405	20050909
US 2006009527	A1	20060112	US 2005-223547	20050909
PRIORITY APPLN. INFO.:			US 2002-357383P	P 20020215
			US 2003-369094	A2 20030214
			US 2004-577089P	P 20040604

IT 302-79-4, Retinoic acid 146426-40-6, Flavopiridol 154361-50-9,  
Capecitabine 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(co-treatment with; use of thioredoxin expression measurements for  
diagnostics and monitoring treatments with histone deacetylase  
inhibitors and other therapeutic agents for hyperproliferative  
diseases)

IT 55-21-0D, Benzamide, derivs. 60-01-5, Tributyrin 79-09-4, Propanoic  
acid, biological studies 89-73-6, Salicylohydroxamic acid 99-66-1,  
Valproic acid 109-52-4, Pentanoic acid, biological studies 122-79-2,  
Phenyl acetate 156-54-7, Sodium butyrate 503-74-2 541-35-5,  
Butyramide 563-83-7, Isobutyramide 590-92-1, 3-Bromopropionic acid  
1821-12-1, Benzenebutanoic acid 4346-18-3, Phenyl butyrate 18992-11-5,  
Azelaic bishydroxamic acid 30240-06-3, MW2996 53342-16-8, Chlamydocin  
58880-19-6, Trichostatin A 68676-88-0, Trichostatin C 83209-65-8,  
HC-toxin 112522-64-2, CI-994 128517-07-7, FR901228 133155-89-2,  
Trapoxin A 136268-96-7, MW2796 139508-73-9, Depudecin  
149647-78-9, Suberoylanilide hydroxamic acid 149647-79-0  
151720-43-3, Oxamflatin 174664-65-4, CBHA 174664-68-7 183506-66-3  
191228-04-3, A-161906 209783-80-2, MS-27-275 209783-80-2D, MS-27-275,  
3'-amino derivs. 258854-10-3, FR225497 287383-59-9, Scriptaid  
382180-17-8, Pyroxamide 414864-00-9, PXD-101 442532-98-1, WF 27082  
591207-53-3, LAQ 824 618056-29-4, CHAP

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(use of thioredoxin expression measurements for diagnostics and  
monitoring treatments with histone deacetylase inhibitors and other  
therapeutic agents for hyperproliferative diseases)



Jagoe

L5 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2005:44347 USPATFULL

TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

INVENTOR(S): Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF  
Dumas, Jacques, Bethany, CT, UNITED STATES  
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF  
Wilhelm, Scott, Orange, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005038080	A1	20050217
APPLICATION INFO.:	US 2004-895985	A1	20040722 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-489102P	20030723 (60)
	US 2004-540326P	20040202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2492	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone  
50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9,  
5-Fluorodeoxyuridine 51-21-8, 5-Fluorouracil 52-24-4, Thiotepa  
53-03-2, Prednisone 53-19-0, Mitotane 55-98-1, Busulfan 56-53-1,  
Diethylstilbestrol 57-22-7, Vincristine 57-85-2, Testosterone  
propionate 58-05-9, Leucovorin 58-96-8, Uridine 59-05-2,  
Methotrexate 71-58-9, Medroxyprogesterone acetate 76-43-7,  
Fluoxymesterone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea  
134-46-3, 5-Fluorodeoxyuridine monophosphate 147-94-4, Cytarabine  
148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine  
305-03-3, Chlorambucil 320-67-2, 5-Azacytidine 446-86-6, Azathioprine  
595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate  
645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4,  
Vinblastine 3778-73-2, Ifosfamide 4291-63-8, Cladribine 4342-03-4,  
Dacarbazine 9015-68-3, Asparaginase 10540-29-1, Tamoxifen  
11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide  
13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin  
18883-66-4, Streptozocin 19767-45-4, Mesna 20830-81-3, Daunorubicin  
23214-92-8, Doxorubicin 25316-40-9, Adriamycin 29767-20-2, Teniposide  
33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin  
51321-79-0 53643-48-4, Vindesine 53910-25-1, Pentostatin  
56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin  
65271-80-9, Mitoxantrone 71486-22-1, Vinorelbine 75607-67-9,  
Fludarabine phosphate 84449-90-1 85622-93-1, Temozolomide  
95058-81-4, 2',2'-Difluorodeoxycytidine 114977-28-5, Docetaxel  
123948-87-8, Topotecan 128517-07-7, FR-901228 149647-78-9,  
Suberoylanilide hydroxamic acid 154361-50-9, Capecitabine  
179324-69-7, Bortezomib 180288-69-1, Trastuzumab 183319-69-9, OSI-774  
184475-35-2, ZD-1839 205923-56-4, Cetuximab 208921-02-2, Tositumomab  
209783-80-2, MS-275 212141-54-3, PTK 787 216974-75-3, Bevacizumab  
220127-57-1, STI-571 257933-82-7, EKB-569 288383-20-0, AZD  
2171 289499-45-2, CI-1033 380610-27-5, Pertuzumab 387867-13-2,  
MLN-518 437755-78-7, GW 2016 443913-73-3, ZD-6474 557795-19-4, SU

Jagoe

11248 591207-53-3, LAQ 824 777080-36-1, AG 13736 804551-71-1, CHIR  
258

(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph  
urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated  
diseases)

L5 ANSWER 6 OF 16 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2005:886301 SCISEARCH

THE GENUINE ARTICLE: 958IV

TITLE: Synergistic interactions between MEK1/2 and histone  
deacetylase inhibitors in BCR/ABL plus human leukemia  
cells

AUTHOR: Yu C; Dasmahapatra G; Dent P; Grant S (Reprint)

CORPORATE SOURCE: Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol  
& Oncol, Massey Canc Ctr, Dept Med, MCV Stn Box 230,  
Richmond, VA 23298 USA (Reprint); Virginia Commonwealth  
Univ, Med Coll Virginia, Div Hematol & Oncol, Massey Canc  
Ctr, Dept Med, Richmond, VA 23298 USA; Virginia  
Commonwealth Univ, Massey Canc Ctr, Dept Biochem,  
Richmond, VA USA; Virginia Commonwealth Univ, Massey Canc  
Ctr, Dept Pharmacol, Richmond, VA USA  
stgrant@hsc.vcu.edu

COUNTRY OF AUTHOR: USA

SOURCE: LEUKEMIA, (SEP 2005) Vol. 19, No. 9, pp. 1579-1589.

ISSN: 0887-6924.

PUBLISHER: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST,  
LONDON N1 9XW, ENGLAND.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 46

ENTRY DATE: Entered STN: 8 Sep 2005

Last Updated on STN: 8 Sep 2005

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB . . . in K562 and LAMA 84 cells. Similar interactions were observed  
in CD34(+) cells from two patients with CML and in **imatinib**  
**mesylate**-resistant K562 cells but not in normal human CD34(+) bone  
marrow cells. These events were associated with a marked increase in. .

STP KeyWords Plus (R): **SUBEROYLANILIDE** HYDROXAMIC ACID; CHRONIC  
MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; KINASE  
INHIBITOR; TYROSINE KINASE; SELECTIVE INHIBITOR; OXIDATIVE STRESS; INDUCE  
APOPTOSIS; IMATINIB. . .

L5 ANSWER 7 OF 16 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on  
STN DUPLICATE

ACCESSION NUMBER: 2005049216 ESBIOBASE

TITLE: New Drugs in Cancer Therapy, National Tumor Institute,  
Naples, 17-18 June 2004

AUTHOR: Caponigro F.; Basile M.; De Rosa V.; Normanno N.

CORPORATE SOURCE: F. Caponigro, National Tumor Institute, Fondazione  
'G.Pascale', via M. Semmola, 80131 Naples, Italy.  
E-mail: caponigrof@libero.it

SOURCE: Anti-Cancer Drugs, (2005), 16/2 (211-221), 61  
reference(s)

CODEN: ANTDEV ISSN: 0959-4973

DOCUMENT TYPE: Journal; Conference Article

COUNTRY: United Kingdom

LANGUAGE: English

Jagoe

SUMMARY LANGUAGE: English

AB. . . in the research on anti-EGFR monoclonal antibodies may be represented by humanized monoclonal antibodies, such as EMD 72000 and ABX-EGF. **Imatinib mesylate** is probably the most outstanding example of an effective targeted therapy-its activity in gastrointestinal stromal tumors was so exciting that. . . for protein folding. Clinical data on depsipeptide, a histone deacetylase (HDAC) inhibitor with activity in T cell lymphoma, were presented. **Suberoylanilide** hydroxamic acid is another small molecular weight inhibitor of HDAC activity. Phase I/ II clinical trials have shown low toxicity. . .

L5 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:269998 CAPLUS

DOCUMENT NUMBER: 140:247047

TITLE: Method of treating leukemia with a combination of suberoylanilide hydroxamic acid and imatinib mesylate

INVENTOR(S): Bhalla, Kapil N.; Nimmanapalli, Ramedevi

PATENT ASSIGNEE(S): University of South Florida, USA

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026234	A2	20040401	WO 2003-US28964	20030919
WO 2004026234	A3	20040708		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2499189	AA	20040401	CA 2003-2499189	20030919
US 2004127571	A1	20040701	US 2003-605283	20030919
EP 1545536	A2	20050629	EP 2003-752375	20030919
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: US 2002-319563P P 20020919  
US 2003-605283 A 20030919  
WO 2003-US28964 W 20030919

IT 149647-78-9, Suberoylanilide hydroxamic acid 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(suberoylanilide hydroxamic acid-imatinib mesylate combination for leukemia treatment)

L5 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2004:252351 CAPLUS

DOCUMENT NUMBER: 140:264488

TITLE: Combination of a benzamide derivative and a histone

10/605283

Jagoe

INVENTOR(S): deacetylase inhibitor for the treatment of leukemia  
Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu,  
Chunrong  
PATENT ASSIGNEE(S): Virginia Commonwealth University, USA; McGuire Va  
Medical Center 111k  
SOURCE: PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024160	A1	20040325	WO 2003-IB4053	20030910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2498210	AA	20040325	CA 2003-2498210	20030910
AU 2003259521	A1	20040430	AU 2003-259521	20030910
BR 2003014112	A	20050712	BR 2003-14112	20030910
EP 1553948	A1	20050720	EP 2003-795175	20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501267	T2	20060112	JP 2004-535791	20030910
PRIORITY APPLN. INFO.:			US 2002-410286P	P 20020913
			US 2002-411344P	P 20020918
			WO 2003-IB4053	W 20030910
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		
IT 156-54-7, Sodium butyrate	58880-19-6, Trichostatin A	128517-07-7, FK 228 149647-78-9, SAHA	152459-95-5 183506-66-3	209783-80-2,
MS 275 220127-57-1, Glivec	404951-53-7	674775-92-9		
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	(combination of histone deacetylase inhibitor and antitumor benzamide derivative for treatment of leukemia)			

L5 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:117798 CAPLUS  
DOCUMENT NUMBER: 140:139491  
TITLE: BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia  
INVENTOR(S): Karato, Masayuki  
PATENT ASSIGNEE(S): Nagoya Industrial Science Research Institute, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

10/605283

Jagoe

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE						
JP 2004043390	A2	20040212	JP 2002-204889	20020712						
PRIORITY APPLN. INFO.:			JP 2002-204889	20020712						
IT 99-66-1, Valproic acid 4346-18-3, Phenylbutyrate 58880-19-6, Trichostatin A 75621-03-3, CHAPs 128517-07-7, FR901228 149647-78-9, SAHA 209783-80-2, MS 27-275 220127-57-1, Imatinib mesylate RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia)										
L5 ANSWER 11 OF 16 TOXCENTER COPYRIGHT 2006 ACS on STN										
ACCESSION NUMBER:		2004:41454 TOXCENTER								
COPYRIGHT:		Copyright 2006 ACS								
DOCUMENT NUMBER:		CA14010139491P								
TITLE:		BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia								
AUTHOR(S):		Karato, Masayuki								
CORPORATE SOURCE:		ASSIGNEE: Nagoya Industrial Science Research Institute								
PATENT INFORMATION:		JP 200443390 A2 12 Feb 2004								
SOURCE:		(2004) Jpn. Kokai Tokkyo Koho, 17 pp. CODEN: JKXXAF.								
COUNTRY:		JAPAN								
DOCUMENT TYPE:		Patent								
FILE SEGMENT:		CAPLUS								
OTHER SOURCE:		CAPLUS 2004:117798								
LANGUAGE:		Japanese								
ENTRY DATE:		Entered STN: 20040224 Last Updated on STN: 20060221								
RN 9076-57-7 (Histone deacetylase) 138238-67-2 (BCR-ABL tyrosine kinase) 99-66-1 (Valproic acid) 4346-18-3 (Phenylbutyrate) 58880-19-6 (Trichostatin A) 75621-03-3 (CHAPs) 128517-07-7 (FR901228) 149647-78-9 (SAHA) 209783-80-2 (MS 27-275) 220127-57-1 (Imatinib mesylate)										
L5 ANSWER 12 OF 16 USPATFULL on STN										
ACCESSION NUMBER:		2004:166081 USPATFULL								
TITLE:		Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate								
INVENTOR(S):		Bhalla, Kapil N., 12902 Magnolia Drive, MRC-3E 3056D, Tampa, FL, UNITED STATES 33612 Nimmanapalli, Ramadevi, 12902 Magnolia Drive, MRC-3E 3056D, Tampa, FL, UNITED STATES 33612								
PATENT ASSIGNEE(S):		UNIVERSITY OF SOUTH FLORIDA, Tampa, FL, UNITED STATES (U.S. corporation)								
<table border="1"><thead><tr><th>NUMBER</th><th>KIND</th><th>DATE</th></tr></thead><tbody><tr><td>US 2004127571</td><td>A1</td><td>20040701</td></tr></tbody></table>					NUMBER	KIND	DATE	US 2004127571	A1	20040701
NUMBER	KIND	DATE								
US 2004127571	A1	20040701								
PATENT INFORMATION:										

10/605283



Jagoe

APPLICATION INFO.: US 2003-605283 A1 20030919 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-319563P	20020919 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SMITH & HOPEN PA, 15950 BAY VISTA DRIVE, SUITE 220, CLEARWATER, FL, 33760	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	235	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 149647-78-9, Suberoylanilide hydroxamic acid 220127-57-1		
, Imatinib mesylate		
(suberoylanilide hydroxamic acid-imatinib mesylate combination for leukemia treatment)		

L5 ANSWER 13 OF 16 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 8

ACCESSION NUMBER: 2003:101336 LIFESCI

TITLE: An activated receptor tyrosine kinase, TEL/PDGF beta R, cooperates with AML1/ETO to induce acute myeloid leukemia in mice

AUTHOR: Grisolan, J.L.; O'Neal, J.; Cain, J.; Tomasson, M.H.

CORPORATE SOURCE: Departments of Medicine and Genetics, Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110; E-mail: Tomasson@im.wustl.edu

SOURCE: Proceedings of the National Academy of Sciences, USA [Proc. Natl. Acad. Sci. USA], (20030805) vol. 100, no. 16, pp. 9506-9511.  
ISSN: 0027-8424.

DOCUMENT TYPE: Journal

FILE SEGMENT: G; B

LANGUAGE: English

SUMMARY LANGUAGE: English

AB . . . unique model of AML to test the efficacy of pharmacological inhibition of histone deacetylase activity by using trichostatin A and **suberoylanilide** hydroxamic acid alone or in combination with the tyrosine kinase inhibitor, **imatinib mesylate**. We found that although imatinib prolonged the survival of treated mice, histone deacetylase inhibitors provided no additional survival benefit. These. .

UT. . . ETO gene; RUNX1 gene; CBF2T1 gene; trichostatin A; Gene fusion; Protein-tyrosine kinase receptors; AML1/ETO gene; platelet-derived growth factor receptors; mice; **suberoylanilide** hydroxamic acid; **imatinib mesylate**

L5 ANSWER 14 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 9

ACCESSION NUMBER: 2003:569832 BIOSIS

DOCUMENT NUMBER: PREV200300562809

TITLE: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

AUTHOR(S): Yu, Chunrong; Rahmani, Mohamed; Conrad, Daniel; Subler, Mark; Dent, Paul; Grant, Steven [Reprint Author]

CORPORATE SOURCE: Division of Hematology/Oncology, Medical College of



Jagoe

Virginia/Virginia Commonwealth University, MCV Station Box  
230, Richmond, VA, 23298, USA  
stgrant@hsc.vcu.edu

SOURCE: Blood, (November 15 2003) Vol. 102, No. 10, pp. 3765-3774.  
print.

CODEN: BLOOAW. ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 3 Dec 2003

Last Updated on STN: 3 Dec 2003

RN . . . 80449-02-1 (Jun kinase)  
155215-87-5 (EC 2.7.1.112)  
80449-02-1 (EC 2.7.1.112)  
616-91-1 (L-N-acetylcysteine)  
179324-69-7 (bortezomib)  
169592-56-7 (caspase-3)  
179241-78-2 (caspase-8)  
9076-57-7 (histone deacetylase)  
220127-57-1 (imatinib mesylate)  
152459-95-5 (imatinib mesylate)  
220127-57-1 (STI571)  
152459-95-5 (STI571)  
165245-96-5 (p38 mitogen-activated protein kinase)  
9026-43-1 (p38 mitogen-activated protein kinase)  
165245-96-5 (EC 2.7.1.37)  
9026-43-1 (EC 2.7.1.37)  
9055-67-8 (poly(ADP-ribose)polymerase)  
58319-92-9 (poly(ADP-ribose)polymerase)  
9055-67-8 (EC 2.4.2.30)  
58319-92-9 (EC 2.4.2.30)  
7782-44-7 (reactive oxygen species)  
156-54-7 (sodium butyrate)  
149647-78-9 (suberoylanilide hydroxamic acid)

L5 ANSWER 15 OF 16 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2003-0513684 PASCAL

COPYRIGHT NOTICE: Copyright .COPYRG. 2003 INIST-CNRS. All rights  
reserved.

TITLE (IN ENGLISH): Cotreatment with the histone deacetylase inhibitor  
suberoylanilide hydroxamic acid (SAHA)  
enhances imatinib-induced apoptosis of  
Bcr-Abl-positive human acute leukemia cells

AUTHOR: NIMMANAPALLI Ramadevi; FUINO Lianne; STOBAUGH Corinne;  
RICHON Victoria; BHALLA Kapil

CORPORATE SOURCE: Department of Interdisciplinary Oncology, Moffitt  
Cancer Center and Research Institute University of  
South Florida, Tampa, United States; Aton Pharma,  
Tarrytown, NY, United States

SOURCE: Blood, (2003), 101(8), 3236-3239, 24 refs.  
ISSN: 0006-4971

DOCUMENT TYPE: Journal

BIBLIOGRAPHIC LEVEL: Analytic

COUNTRY: United States

LANGUAGE: English

AVAILABILITY: INIST-3178, 354000119367220470

TIEN Cotreatment with the histone deacetylase inhibitor  
suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced  
apoptosis of Bcr-Abl-positive human acute leukemia cells

Jagoe

AB Here we demonstrate that treatment with SAHA (**suberoylanilide hydroxamic acid**), a known inhibitor of histone deacetylases (HDACs), alone induced p21 and/or p27 expressions but decreased the mRNA and.

CT. . . inhibitor; Biological activity; Antineoplastic agent; Drug combination; Apoptosis; Chromosome translocation; Abnormal chromosome C9; Abnormal chromosome G22; Philadelphia chromosome; Human; Blast; **Imatinib mesylate**

CTFR. . . biologique; Anticancereux; Association medicamenteuse; Apoptose; Translocation chromosomique; Chromosome C9 anormal; Chromosome G22 anormal; Chromosome Ph1; Homme; Histone deacetylase; Gene bcr; **Suberoylanilide hydroxamic acid**; Cellule blastique; Mesilate d'imatinib

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 10

ACCESSION NUMBER: 2003:249361 BIOSIS  
DOCUMENT NUMBER: PREV200300249361  
TITLE: Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.  
AUTHOR(S): Yu, Chunrong; Rahmani, Mohamed; Almenara, Jorge; Subler, Mark; Krystal, Geoffrey; Conrad, Daniel; Varticovski, Lubya; Dent, Paul; Grant, Steven [Reprint Author]  
CORPORATE SOURCE: Division of Hematology/Oncology, Virginia Commonwealth University/Medical College of Virginia, MCV Station Box 230, Richmond, VA, 23298, USA  
stgrant@hsc.vcu.edu  
SOURCE: Cancer Research, (May 1 2003) Vol. 63, No. 9, pp. 2118-2126. print.  
ISSN: 0008-5472 (ISSN print).  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 28 May 2003  
Last Updated on STN: 28 May 2003

RN 152459-95-5 (STI571)  
142243-02-5 (extracellular signal-regulated kinase)  
9076-57-7 (histone deacetylase)  
220127-57-1 (imatinib mesylate)  
142805-58-1 (mitogen activated protein kinase kinase)  
9026-43-1 (mitogen activated protein kinase kinase)  
142805-58-1 (EC 2.7.1.37)  
9026-43-1 (EC 2.7.1.37)  
149647-78-9 (suberoylanilide hydroxamic acid)  
149647-78-9 (SAHA)

=> d his

(FILE 'HOME' ENTERED AT 14:27:05 ON 18 MAR 2006)

FILE 'REGISTRY' ENTERED AT 14:27:16 ON 18 MAR 2006

L1 1 S IMATINIB MESYLATE  
L2 0 S SUBEROYLANILIDE HYDROMAXIC ACID  
L3 1 S SUBEROYLANILIDE

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI,

Jagoe

MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, ...' ENTERED AT 14:28:20 ON  
18 MAR 2006

L4 36 S L1 AND L3

L5 16 DUP REM L4 (20 DUPLICATES REMOVED)